Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma

BACKGROUND: Cabozantinib, a standard of care metastatic renal cell carcinoma (mRCC), may be associated with weight and muscle loss. These effects of new generation VEGFR tyrosine kinase inhibitor on muscle mass loss are poorly described. METHODS: All cabozantinib‐treated mRCC patients from January 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Colomba, Emeline, Alves Costa Silva, Carolina, Le Teuff, Gwénaël, Elmawieh, Jamie, Afonso, Daniel, Benchimol‐Zouari, Axelle, Guida, Annalisa, Derosa, Lisa, Flippot, Ronan, Raynard, Bruno, Escudier, Bernard, Bidault, François, Albiges, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530538/
https://www.ncbi.nlm.nih.gov/pubmed/35903892
http://dx.doi.org/10.1002/jcsm.13021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530538/
https://www.ncbi.nlm.nih.gov/pubmed/35903892
http://dx.doi.org/10.1002/jcsm.13021

Ejemplares similares